AstraZeneca: Number of Employees 2010-2023 | AZN

Interactive chart of AstraZeneca (AZN) annual worldwide employee count from 2010 to 2023.
  • AstraZeneca total number of employees in 2023 was 89,900, a 7.66% increase from 2022.
  • AstraZeneca total number of employees in 2022 was 83,500, a 0.48% increase from 2021.
  • AstraZeneca total number of employees in 2021 was 83,100, a 9.2% increase from 2020.
  • AstraZeneca total number of employees in 2020 was 76,100, a 7.79% increase from 2019.
AstraZeneca Annual Employee Count
2023 89,900
2022 83,500
2021 83,100
2020 76,100
2019 70,600
2018 64,400
2017 61,100
2016 59,700
2015 61,500
2014 57,500
2013 51,500
2012 51,700
2011 59,800
2010 61,000
2009 62,700
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $219.666B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77